Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance - Wikidata - wikimedia - TriplyDB

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance

http://www.wikidata.org/entity/Q33396832

about

Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers Genomic screening with RNAi: results and challenges Cancer systems biology: a network modeling perspective Logical Modeling and Dynamical Analysis of Cellular Networks Network-based approaches in drug discovery and early development SBML qualitative models: a model representation format and infrastructure to foster interactions between qualitative modelling formalisms and tools Systems biology approaches for advancing the discovery of effective drug combinations The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli A comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cells Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling The Cell Collective: toward an open and collaborative approach to systems biology.Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors CellNOptR: a flexible toolkit to train protein signaling networks to data using multiple logic formalisms.Dynamics of p53 and NF-κB regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention.Deterministic Effects Propagation Networks for reconstructing protein signaling networks from multiple interventions HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.Time-resolved human kinome RNAi screen identifies a network regulating mitotic-events as early regulators of cell proliferation.ADAM: analysis of discrete models of biological systems using computer algebra.Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells Construction of large signaling pathways using an adaptive perturbation approach with phosphoproteomic data.A new analysis approach of epidermal growth factor receptor pathway activation patterns provides insights into cetuximab resistance mechanisms in head and neck cancer Continuous time Boolean modeling for biological signaling: application of Gillespie algorithm.Bio-logic builder: a non-technical tool for building dynamical, qualitative models.RNAi-based validation of antibodies for reverse phase protein arrays.Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer.Integrating Bayesian variable selection with Modular Response Analysis to infer biochemical network topology MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.Network based elucidation of drug response: from modulators to targets.Sensitivity analysis of biological Boolean networks using information fusion based on nonadditive set functions Steady state analysis of Boolean molecular network models via model reduction and computational algebra.Microenvironmental stiffness enhances glioma cell proliferation by stimulating epidermal growth factor receptor signaling.Reconciling molecular regulatory mechanisms with noise patterns of bacterial metabolic promoters in induced and repressed states.MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology.Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.Dynamical systems approach to endothelial heterogeneity.

P2860

Q24294953-5BDB5631-6937-43C4-9B6A-D16A391A9AFC Q24626537-F2F3CAF4-B99F-4901-91C1-C427CB1AC2C1 Q24650086-556D1CD1-6FB9-4970-8D0A-7C3566858F81 Q26745955-EC2F6F72-E7D3-471A-A88B-F5923FE37E31 Q26827940-B51060B4-E955-47BF-8B0A-EEC74A3CD9CF Q27499050-472D8927-9C16-4972-8F90-AE11BFCDACA1 Q27702922-31A4B32D-9B90-4D3B-8555-E077440D6819 Q28468629-573DF296-EA58-45DD-8530-3A3A270AE56B Q28477321-F796C41E-D346-4711-AF2C-37B7DA3307F3 Q28486292-C9AF7163-7358-4662-943F-2BA5A079E924 Q28547862-C3E9F858-4936-4886-9E39-C04CEE5145ED Q28727777-4183796E-BF33-43DA-ABED-8E4A50D3EC70 Q28817295-BFEA7F15-00A1-453E-8A1A-4B3ADEC6475E Q30573980-AC170429-0032-4BD8-943A-5F30F0203901 Q31090728-0573048F-F757-41FE-9CE7-9603B45D996F Q33509376-6BC27A4D-DBD1-4AFB-A923-509E83DB3E35 Q33626569-B92146E8-12A4-4429-9AE5-3EB1767ABD35 Q33737298-143AE04A-717E-4D59-A9D1-B51EE1B490EF Q33864932-5288D061-30D2-4FE2-86A1-00C777A636F6 Q33963929-E9D16F0B-704F-4A78-9A8F-B37D6805C10C Q33966533-88337F91-BC12-4453-B090-199AB85BAF79 Q34192940-A1894D78-1EF5-4615-87A7-1277243733B9 Q34207814-D76870B3-19B8-4B8F-A757-B8F9610011F2 Q34252978-6D654856-D6C6-4E9C-A6BB-EE8AA9A3972F Q34397609-EBC32F84-1879-40FF-AD21-13EEB9603C8D Q34451885-5B94B4BC-1BD6-420D-A82A-485BCCEA269F Q34500104-E60B379C-2EEB-44B4-B1AB-5A71726444D1 Q34635861-F523D84F-E420-4729-8000-ED5F2D98BEE6 Q34800432-7B9E366A-7A82-40A7-AE45-F5DB3172A30A Q34984068-BAD1062A-7BB1-4488-9017-8F9FA78731BA Q35065347-728DA154-164E-49FF-B668-2025C59CE3B2 Q35189160-9D40EEEA-2BE3-48E3-8A3E-5A4892092E4C Q35194958-7F751951-0A7C-4562-9DA6-C379A23747AC Q35202307-F41EB829-3762-4EB0-AFAA-B304198DA257 Q35657684-5E012210-F52A-4FF3-9209-4B084222B382 Q35697850-21A8E5DB-A654-4307-BC8D-BB99FAD629E6 Q35770840-2385C2E5-AB4D-4042-A8FA-13CE669BC639 Q35813685-DEFF5B4F-DC85-4A9B-A17B-A3251CD5A987 Q35962054-59538FD3-991F-4F15-B170-96813F225C07 Q36104888-BC98EADB-B3AB-478A-BCC4-E9F6639A7C66

P2860

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance

http://www.wikidata.org/entity/Q33396832

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Modeling ERBB receptor-regulat ...... de novo trastuzumab resistance

@ast

Modeling ERBB receptor-regulat ...... de novo trastuzumab resistance

@en

type

label

Modeling ERBB receptor-regulat ...... de novo trastuzumab resistance

@ast

Modeling ERBB receptor-regulat ...... de novo trastuzumab resistance

@en

prefLabel

Modeling ERBB receptor-regulat ...... de novo trastuzumab resistance

@ast

Modeling ERBB receptor-regulat ...... de novo trastuzumab resistance

@en

P1433

Q33396832-340BB9BB-345E-4423-8EFE-1E629127025A

P1476

Q33396832-F64CAA95-CB25-4045-85C7-1B4E4B561B9A

P2093

Q33396832-080EBAA2-ABCC-4389-B3A1-C91F53E1361B

Q33396832-3F79D904-AD1E-4A4E-ABBE-5D42268E30BA

Q33396832-44820513-F949-4B16-ACEB-0014618A4D08

Q33396832-68B35D32-7CFA-488E-B052-BE185D10956C

Q33396832-6AF47B5E-0FF6-434F-8879-F853C9873C37

Q33396832-95D7A4FB-6DBD-429E-9ED4-05B7FE3A6F0D

Q33396832-A18A265A-DA66-4142-84B1-994EBE0A09CE

Q33396832-BB4220C5-B62B-4434-95F4-CD82AA7AE0F6

P2860

Q33396832-0059CA9A-8F8F-4AE3-A909-16AA71D10EDF

Q33396832-072DE2FD-9016-4D7B-8ABE-F9D305173003

Q33396832-0A649BA1-9B25-451B-894F-B228F065ADC2

Q33396832-0BA3E1BF-8348-43DD-B3A3-056AAEB9E435

Q33396832-18594789-7CE4-4B65-B674-B54E0CCC9D47

Q33396832-24C779C6-4D5F-4D0C-8595-5B5D7923DC07

Q33396832-3146A81A-3A58-4AE5-BF84-96B6C7FCC32F

Q33396832-35A690CF-9126-4F74-8BC2-DE2CAE4DB026

Q33396832-39AA8029-EC19-46BD-ABB1-C11D0E63E596

Q33396832-4E2EC918-4057-4130-8962-DDAF14DC6E41

P2888

Q33396832-3D1D8DCE-DDB1-4295-B667-CE59B6E45A55

P304

Q33396832-B373DB50-0358-4FD5-87B7-CD202FBFEF48

P31

Q33396832-BB4D5584-CA2A-4A5D-AF7B-BECBE8DB36A9

P356

Q33396832-93955793-1E43-4121-9D42-9DFDF854C81F

P478

Q33396832-928DD68B-96EF-42AB-BECC-155618F998E7

P50

Q33396832-0B77805A-8E65-47DB-9E77-FFFF5EE22BE0

Q33396832-1B3849AD-7533-4AB3-B38E-F50CB959DE50

Q33396832-5120437A-65D6-4C29-8738-384B22AF51A3

Q33396832-ACDCE5F5-7CD0-428C-8765-691DD84B8577

Q33396832-C09A9B80-4C42-4FFA-90AE-2E63A769A623

Q33396832-F4D5CD17-5A1B-4173-953B-B72ECC17747F

P577

Q33396832-D26AD666-B60C-4A3D-8CBF-00B7062445CD

P5875

Q33396832-21391119-D3D5-4239-B1FE-CB1BFC624E06

P6179

Q33396832-8E01AA5D-A6A4-4420-A3D0-AD54D6D079C8

P698

Q33396832-72FC2E35-3412-4196-ADAF-949ABE551664

P932

Q33396832-4F5F48A2-020C-47A7-810C-17DE631207BC

P356

P1433

BMC Systems Biology

P1476

Modeling ERBB receptor-regulat ...... de novo trastuzumab resistance

@en

P2093

Christian Löbke

http://www.w3.org/2001/XMLSchema#string

Dorit Arlt

http://www.w3.org/2001/XMLSchema#string

Ingo Schupp

http://www.w3.org/2001/XMLSchema#string

Jens Mattern

http://www.w3.org/2001/XMLSchema#string

Meher Majety

http://www.w3.org/2001/XMLSchema#string

Ozgür Sahin

http://www.w3.org/2001/XMLSchema#string

Sara Burmester

http://www.w3.org/2001/XMLSchema#string

Tim Beissbarth

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

The regulation of E2F by pRB-family proteins

HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways

Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data

Drug-target network

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

EGF-ERBB signalling: towards the systems level

P2888

P304

1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1752-0509-3-1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Claudine Chaouiya

Holger Fröhlich

Annemarie Poustka

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23715684

http://www.w3.org/2001/XMLSchema#string

P6179

1049490622

http://www.w3.org/2001/XMLSchema#string

P698

19118495

http://www.w3.org/2001/XMLSchema#string

P932

2652436

http://www.w3.org/2001/XMLSchema#string